What is Semax?
In short: Semax is a synthetic heptapeptide developed in Russia, sold in vial and nasal formats for research use only. It is studied in cognitive and neurological research; the human literature is small and mostly Russian. Semax has never been through FDA drug review and is not approved for any human use - the July 2026 advisory review was not a drug approval. A July 2026 FDA advisory vote (8-5-1) recommended it for the 503A Bulks List, changing nothing in law.
Semax is a synthetic peptide developed in Russia and studied in cognitive and neurological research. It is sold in both lyophilized-vial and nasal formats; much of the published research used nasal administration.
The basics
- Type: a synthetic heptapeptide - a modified fragment related to the ACTH(4-7) sequence with an added stabilizing tripeptide.
- Origin: developed by Russian researchers; a Semax preparation has been registered in Russia in nasal-drop form. That registration has no standing with the FDA.
- Research focus: laboratory and small clinical studies examine Semax in relation to cognitive and neuroprotective questions.
- Formats sold: nasal spray bottles (listed around $42) and lyophilized vials, commonly 10 mg.
What the evidence actually shows
The human literature on Semax consists of small studies, predominantly Russian, that have never been through FDA review. That is a thinner base than marketing in this niche usually implies. Claims circulating in vendor copy about the nasal format's absorption come from guides and sellers, not from FDA-reviewed data, and should be read as claims.
Semax is frequently sold alongside Selank, a related research peptide studied in anxiety research, also in small Russian trials. Selank is the more commoditised of the two: price tracking (PeptidePrices, checked 23 October 2026) found 200 vendors and 228 listings at a median of $39.99 per 10 mg, with 118 listings carrying verified COAs - a useful benchmark for what "normal" pricing and testing look like in this market.
Regulatory status (October 2026)
At the FDA's Pharmacy Compounding Advisory Committee meeting on 23-24 July 2026, Semax received an 8-5-1 vote to recommend adding it to the 503A Bulks List. The same caveats apply as for every compound in that vote:
- The recommendation is advisory only. Semax is not on the 503A Bulks List, and 503A pharmacies cannot lawfully compound it as of October 2026.
- FDA staff recommended against it at the same meeting.
- Selank was not among the compounds voted on in July 2026.
What Semax costs
Retail listings for Semax 10 mg vary widely between vendors - among the widest spreads of any compound we track. The spread between the cheapest and most expensive listings for identical items is the story of this whole market; the tracked ranges for every compound we cover are on the price-comparison page.
What to check before buying any research peptide
- Batch-specific COA from third-party testing, tied to the lot you receive.
- Identity + purity methods stated on the COA (HPLC and mass spectrometry).
- Format honesty: a nasal product and a lyophilized vial are different formats with different research contexts; vendor copy that blurs them is a red flag.
Our own store is in preparation. When it launches, every batch will carry a published COA per lot, priced against the tracked ranges above.
Bench Grade's published affiliate terms give first-time referred customers an extra 10% off their first order. Sold for laboratory research use only.
Related reading
- What is MOTS-c? - the longevity-research counterpart from the same July 2026 vote.
- Research peptide price comparison - including Selank's 200-vendor benchmark.
- FAQ: what the July 2026 FDA votes actually changed